VTT-originated Spectral Engines creates portable device for rapid screening of suspected drugs

NewsGuard 100/100 Score

Spectral Engines, a growth company that originated at VTT Technical Research Centre of Finland, is about to launch a portable drug screening device police patrols can use for rapid and cost-efficient on-site screening of suspected drugs. The pocket-size scanner reports the results in the user's mobile phone in a matter of seconds. There is also international demand for such an innovation, and therefore a total of EUR 2.4 million in EU funding was granted for the device's productization.

The newly developed small device, weighing only a few hundred grams, will change the future of police work in war on drugs. Besides being the first pocket-size drug screening device available for field work, the device is also more than 20 times cheaper than any other devices in current use.

"Our drug screening device is significantly smaller than the competing ones currently on the market. The device is designed for field work and it uses the mobile phone as its user interface. Devices are cloud-connected which enables easy machine learning-based application algorithm development for different drugs," says the company's CCO Janne Suhonen.

The Spectral Engines scanner allows an accurate and reliable identification of such drugs as cocaine, heroin, and amphetamine from very low drug concentrations. As needed, the multi-purpose device's identification algorithms can be updated to identify various designer drugs as well.

In addition to police use, the scanner is also suited for the use of the customs, the military and other similar organizations, where it may be important to identify foreign substances.

The technology of the device created in the NarcoScan project is based on infrared spectroscopy and the MEMS technology studied at VTT.

First products to enter market next spring

The competitive funding from the EU Horizon 2020 programme won by Spectral Engines enables rapid and cost-efficient productization of the drug screening device.

"The EU funding guarantees that we can proceed rapidly from the first prototype to mass production, and allows us to assign several man-years of labor on this productization project. We will be able to launch the first products next spring, and early next year we will also begin field testing with the first pilot customers", Suhonen says.

The company has already collaborated with the leading criminal laboratories, and its research partners come mainly from the United States and Europe. The EU funding enables expanding the cooperation to various new laboratories for the development of model libraries.

The granted funding provides also a solid foundation for rapid growth of Spectral Engines. With the help of the funding, the company will also be able to develop portable sensor technology and cloud computing solutions for other applications. VTT Ventures Oy is one of the funding bodies of Spectral Engines.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rising antibiotic resistance prompts shift to ecological research strategies in infection control